---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020572"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:33:40.009379+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q1 rev $107.6M (+11% YoY); raises FY2023 revenue to $454-466M

## Summary
- Net revenue $107.6M, up 11% YoY; net loss $3.0M vs $0.9M loss year-ago.
- Advanced Wound Care revenue $100.9M (+12% YoY); Surgical & Sports Medicine $6.7M (-4% YoY).
- Adjusted EBITDA $3.8M vs $5.0M prior year; adjusted net loss $0.7M.
- FY2023 guidance raised: revenue $454-466M, net income $3-11M, adjusted EBITDA $38-49M.
- Cash $88.7M, debt $69.9M at March 31, 2023.

## SEC filing metadata
- accession: 0000950170-23-020572
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/0000950170-23-020572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/orgo-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020572
- JSON: https://secwatch.observer/filing/0000950170-23-020572.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020572.txt

## Key facts
- Earnings Releases
  Organogenesis Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $107.6 million, net income Net loss of $3.0 million, EPS $(0.02) per share. Guidance raised.
  - Period: first quarter ended March 31, 2023
  - Revenue: $107.6 million
  - Net income: Net loss of $3.0 million
  - EPS: $(0.02) per share
  - Guidance: raised
  - Result: reported results
  source text: Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Summary: • Net revenue of $107.6 million for the first quarter of 2023, an increase of $10.5 million compared to net revenue of $97.1 million for the first quarter of 2022. Net revenue for the first quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017023020572/0000950170-23-020572-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.